瑞舒伐他汀钙片强化降脂在冠心病患者治疗中的作用

Rosuvastatin Calcium Tablets intensive lipid-lowering therapy in patients with coronary heart disease

目的:研究瑞舒伐他汀钙片强化降脂在冠心病患者临床治疗中的作用。方法:将2015年8月—2016年9月我院76例冠心病病例纳入研究对象,遵循随机原则将其平均分为两组,A组服用低剂量瑞舒伐他汀钙片,B组服用高剂量瑞舒伐他汀钙片,比较两组治疗前后血脂指标、脂联素(APN)、疗效及不良反应。结果:治疗后,两组TC、TG、HDL-C、LDL-L水平均明显降低,且APN水平均明显升高(P<0.05),B组患者血清TC、TG、HDL-C、LDL-L水平明显低于A组,APN水平明显高于A组(P<0.05);B组临床疗效总有效率为94.74%,高于A组73.68%(P<0.05);两组不良反应总发生率的比较无明显差异(P>0.05)。结论:对冠心病患者予以高剂量瑞舒伐他汀钙片进行强化降脂治疗,可有效调节血脂异常,显著升高APN水平,疗效确切,同时不良反应少,改善患者预后。

Objective To study the effects of Rosuvastatin Calcium Tablets intensive lipid-lowering therapy in the treatment of coronary heart disease （CHD）. Methods 76 cases of patients with CHD treated in our hospital during August 2015 to September 2016 were enrolled in the study, and they were randomly divided into two groups. Group A was treated with low-dose Rosuvastatin Calcium Tablets while group B was treated with high-dose Rosuvastatin Calcium Tablets. The blood lipid indexes, adiponectin （APN）, efficacy and adverse reactions were compared between the two groups. Results After treatment, levels ofT（：, TG, HDL-C and LDL-L were significantly decreased, and the levels of APN were significantly increased in the two groups （P 〈 0.05）, and the changes of above indexes were more significant in group B than in group A （P 〈 0.05）. The total effective rate of treatment in group B was higher than that in group A （94.74% vs 73.680/6） （P 〈 0.05）, and there was no significant difference in the total incidence of adverse reactions between the two groups （P 〉 0.05）. Conclusion The application of high-dose Rosuvastatin Calcium Tablets in intensive lipid-lowering therapy for patients with CHD can effectively regulate dyslipidemia, and significantly increase APN levels, with few adverse reactions, and it can improve the prognosis of patients.